Tuan Vo-Dinh*1, Yang Liu1, Bridget M Crawford1, Hsin-Neng Wang1, Hsiangkuo Yuan1, Janna K Register1, Christopher G Khoury1
1Fitzpatrick Institute for Photonics, Department of Biomedical Engineering, Department of Chemistry, Duke University, Durham, NC 27708-0281, USA
Cancer has been a significant threat to human health with more than eight million deaths each year in the world. There is an urgent need to develop novel methods to improve cancer management. Biocompatible gold nanostars (GNS) with tip-enhanced electromagnetic and optical properties have been developed and applied for multifunctional cancer diagnostics and therapy (theranostics). The GNS platform can be used for multiple sensing, imaging and treatment modalities, such as surface-enhanced Raman scattering, two-photon photoluminescence, magnetic resonance imaging and computed tomography as well as photothermal therapy and immunotherapy. GNS-mediated photothermal therapy combined with checkpoint immunotherapy has been found to reverse tumor-mediated immunosuppression, leading to the treatment of not only primary tumors but also cancer metastasis as well as inducing effective long-lasting immunity, i.e. an anticancer ‘vaccine’ effect.DOI: 10.29245/2578-3009/2018/1.1104 View / Download Pdf View Full Text
Nicholas L. Cianciolaa,d and Cathleen R. Carlina,b,*
aDepartments of Molecular Biology and Microbiology, School of Medicine, Case Western Reserve University, Cleveland, Ohio 44106
bThe Case Comprehensive Cancer Center, School of Medicine, Case Western Reserve University, Cleveland, Ohio 44106
dThe Lockwood Group, Stamford, CT 06901
The interplay between viruses and host factors regulating inflammatory or cytotoxic responses directed against infected cells is well documented. Viruses have evolved a wide array of mechanisms that strike a balance between the elimination of virus and immune-mediated tissue injury by antiviral immune responses. The topic of this mini-review is a series of recent studies demonstrating a link between cholesterol trafficking and innate immune responses in cells infected with human adenoviruses that provide the backbone of commonly used vectors in gene medicine. Besides revealing an unexpected role for lipid metabolism in immune evasion, these studies have important implications for understanding the molecular basis of cholesterol trafficking in normal cells and various disease states. They also describe a previously unappreciated host-virus interaction that may be employed by other pathogens to interfere with the host innate immune system.DOI: 10.29245/2578-3009/2018/1.1112 View / Download Pdf View Full Text
Sarah Alter1, Peter R. Rhode1, Emily K. Jeng1, and Hing C. Wong1*
1Altor BioScience, Miramar, Florida
This mini review provides an overview and rationale for creating IL-15-based fusion protein complexes to be used as targeted immunotherapeutic agents. IL-15 stimulates proliferation and activation of CD8+ T and natural killer cells which result in augmentation of their anti-tumor activities. We have created ALT-803, an IL-15 superagonist complex which exhibits longer serum half-life, longer retention in lymphoid tissues, and better immunostimulatory and anti-tumor activities compared to native IL-15. When used alone or in combination with other immunotherapeutic molecules in various mouse tumor models, ALT-803 effectively reduces tumor burden and prolongs survival by stimulating the innate and adaptive arms of the immune system. To evaluate whether ALT-803 could be used as a protein scaffold to create IL-15-based tumor cell-specific molecules, we genetically fused it with a single chain anti-CD20 antibody derived from the variable regions of rituximab. This novel fusion protein exhibits enhanced anti-tumor activity compared to rituximab while maintaining IL-15 immunostimulating properties. Thus, ALT-803 may be exploited as a versatile scaffold to produce multivalent targeted fusion proteins to improve the anti-tumor efficacy of other therapeutic agents in the clinic.DOI: 10.29245/2578-3009/2018/1.1111 View / Download Pdf View Full Text
DOI: 10.29245/2578-3009/2018/1.1114 View / Download Pdf View Full Text
W. Jean Dodds1*
1Hemopet, 938 Stanford Street, Santa Monica, California 90403, USA
DOI: 10.29245/2578-3009/2018/1.1110 View / Download Pdf View Full Text
Laura Pulze1, Miriam Capri2, Annalisa Grimaldi1, Stefano Salvioli2, Gianluca Tettamanti1, Magda de Eguileor1*
1University of Insubria, Department of Biotechnology and Life Sciences, 21100 Varese, Italy
2University of Bologna, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), 40126 Bologna, Italy
1Genome Damage and Stability Centre, School of Life Sciences, University of Sussex, Falmer, Brighton BN1 9RH, UK.
ATM kinase is a master regulator of the DNA damage response (DDR). A recently published report from the d’Adda di Fagagna laboratory1 sheds a light onto our understanding of ATM activation. In this short-commentary we will expand on this and other work to perceive better some of the aspects of ATM regulation.DOI: 10.29245/2578-3009/2018/1.1108 View / Download Pdf View Full Text
Manuela M Almo1, Isabel G Sousa2, Andréa Q Maranhão2,3, Marcelo M Brigido2,3*
1Molecular Pathology Graduation Program, Medicine Faculty, University of Brasilia, Brasilia, Brazil
2Department of Cell Biology, Institute of Biological Sciences, University of Brasilia, Brasilia, Brazil
3Institute for Immunology Investigation, a National Institute of Science and Technology
Long noncoding RNAs (lncRNAs) are regulatory RNA molecules that are involved in various biological processes. In the immune system, the lncRNAs play important roles in development, differentiation, survival, cell fate determination, proliferation and activation of immune cells. Lymphocytes are the main players of the adaptive immunity and CD3+ T cells acts as a master regulator for the immune responses. These cells following activation by antigens and co-stimulatory signals are differentiated into various effector T cell subsets, including CD4 and CD8 T cells. These heterogeneous populations can be distinguished based on molecular surface markers and subsets of these markers can be used to denote various stages of T lymphocyte differentiation, notwithstanding the CD3+ T cells phenotypes are markedly influenced by lncRNAs. In the present review, we summarize recent research on the role of long noncoding RNAs in subtypes of CD4+ and CD8+ human T cells.DOI: 10.29245/2578-3009/2018/2.1.1109 View / Download Pdf View Full Text
Fatemah Salem Basingab1,2 and David John Morgan1*
1Department of Cellular and Molecular Medicine, University of Bristol, School of Biomedical Sciences, University Walk, Bristol BS8 1TD, UK.
2Department of Biology, Faculty of Science, King Abdulaziz University, PO Box 80203, Jeddah 21589, Kingdom of Saudi Arabia
Tumour-infiltrating cytotoxic T lymphocytes (CTLs) play a key role in tumour killing. However, many cancers adopt various strategies to induce immunosuppression. Priming of naïve CD8+ T cells to become CTLs occurs via cognate interactions of the T cell receptor (TcR) and CD28 with tumour-derived peptide epitopes expressed on major histocompatibility complex (MHC) class I molecules and CD80/CD86 on T cells and antigen-presenting cells (APCs) respectively. Here we report that, in the absence of CD80/CD86 expression by renal carcinoma (Renca) cells, expression of intercellular adhesion molecule-1 (ICAM-1) by Renca cells provides a potent alternative co-stimulation to a tumour-specific CD8+ T cells causing them to produce interferon gamma (IFN-γ) which is crucial for the further up-regulation of ICAM-1 on tumour cells. We have shown that overexpression of cyclooxygenase-2 (COX-2), by Renca cells (Renca-T3), results in increased levels of prostaglandin (PG) E2 production, which can directly suppress anti-tumour CD8+ T cells resulting in loss of CTL function in vivo and cause metastases to the tumor-draining lymph nodes (TDLNs). Significantly, our data also show that overexpression of ICAM-1 on Renca-T3 cells can counteract the immune-suppressive effect of PGE2 and restore CTL responses.DOI: 10.29245/2578-3009/2018/1.1115 View / Download Pdf View Full Text
Enrico Bracco2*, Cristina Panuzzo1, Barbara Pergolizzi1*
1Dept. of Clinical & Biological Sciences, University of Turin, Italy
2Dept. of Oncology, University of Turin, Italy
HECT ubiquitin ligases are key components of the eukaryotic ubiquitin-proteasome system controlling different cellular physiological aspects as well as the genesis of several human diseases. Among the HECT family, the HERC subfamily members are characterized by having one or more RCC1-like domains, a C-terminal HECT domain and the molecular mass ranging approximately from 120 kDa to 500 kDa. Due to their large size, some of them are refractory to functional characterization. We have recently identified and functionally characterized a novel large HECT member in Dictyostelium discoideum that, in many aspects, exhibits structural similarities with the mammalian large HERC1. In the present minireview, we shortly summarize and revise the current phylogenetic history of HERC proteins among the different living organisms.DOI: 10.29245/2578-3009/2018/1.1113 View / Download Pdf View Full Text
DOI: 10.29245/2578-3009/2018/1.1116 View / Download Pdf View Full Text
Kara D. Capriotti1,2*
1Veloce BioPharma LLC, 1007 N Federal Hwy #E4, Fort Lauderdale, FL 33304
2Bryn Mawr Skin and Cancer Institute, 919 Conestoga Road, Building 2, Suite 106, Rosemont, PA 19010
DOI: 10.29245/2578-3009/2018/1.1123 View / Download Pdf View Full Text
Zulfia Hussain1, Junaid Ali Khan1*
1Institute of Pharmacy, Physiology and Pharmacology, University of Agriculture Faisalabad (UAF)-38040, Pakistan
DOI: 10.29245/2578-3009/2018/1.1119 View / Download Pdf View Full Text
Diego Salas-Benito1,2, Noelia Casares2,3, Pablo Sarobe2,3, Juan José Lasarte2,3 and Sandra Hervas-Stubbs2,3*
1Oncology Department, University Clinic, University of Navarra, Spain.
2Instituto de Investigación Sanitaria de Navarra (IdISNA), Spain.
3Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), University of Navarra, Spain.
Laura Comi1*, Elisa Di Filippo1, Franco Maggiolo1
1Division of Infectious Diseases, ASST Papa Giovanni XXIII, Bergamo, Italy
Introduction: The use of combination antiretroviral therapy (cART) containing three active drugs from at least two different classes is the standard of care for HIV treatment worldwide. The availability of newer drugs with improved potency and tolerability and higher barrier to the development of resistance allows exploring the feasibility of ARV-sparing strategies, namely dual therapies. A dual therapy based on dolutegravir plus lamivudine could be an intriguing simplification strategy for individuals with stable HIV suppression on cART.
Results: Seven studies of dual therapy regimens based on dolutegravir plus lamivudine were critiqued. All of them report a low rate of therapeutic failure due to any cause and a small number of virologic failures. More important virologic failures were not associated with loss of future option as no resistance inducing mutation to ongoing drugs emerged. On the safety side, after the switch, very few short-term adverse events leading to treatment discontinuation were observed and surrogate markers of long term toxicities such as changes in lipid profile and renal function were minimally influenced or improved.
Discussion: Dolutegravir plus lamivudine as a switch option in patients with sustained viral control is still to be considered an experimental approach. Although small in number and heterogeneous in nature the studies that evaluated the effectiveness of dolutegravir plus lamivudine dual therapy have documented substantial virologic efficacy and tolerability of the regimen without exposing patients to the risk of selecting for INSTI-inducing resistance mutations.DOI: 10.29245/2578-3009/2018/1.1120 View / Download Pdf View Full Text
Xiaofeng Ding1, Shuanglin Xiang1*
1Key Laboratory of Protein Chemistry and Development Biology of State Education Ministry of China, College of Life Science, Hunan Normal University, Changsha, P.R. China
Endocytosis is critical for normal cellular function through clearing foreign materials and protecting the host from pathogen/virus attack. Innate immune cells play important roles in specifically recognizing and degrading microbes by generating phagosomes and phagolysosomes. However, the knowledge of how innate immunity regulates endocytosis in vitro and in vivo remains limited. In this review, we attempt to systematically and comprehensively summarize our current understanding of endocytosis and the role of Rab GTPases in the innate immune system. Understanding the immunity mechanisms of endocytosis might help develop targeted therapeutics for various applications, including viral inactivation and clearance, pathogen removal and even adjuvant-enhanced antibody responses.DOI: 10.29245/2578-3009/2018/1.1121 View / Download Pdf View Full Text